The Impact of Immune-Modulating Treatments for Dermatological Diseases on the Risk of Infection with SARS-CoV-2 and Outcomes Associated with COVID-19 Illness.
Nicole MaynardApril W ArmstrongPublished in: Current dermatology reports (2023)
Based on current research and guidelines from the American Academy of Dermatology and the National Psoriasis Foundation, dermatology patients on immune-modulating therapies can continue treatment during the COVID-19 pandemic when they are not infected with SARS-CoV-2. For patients who have COVID-19, guidelines encourage individualized assessment of the benefits and risks of continuing or temporarily withholding treatment.
Keyphrases
- sars cov
- end stage renal disease
- newly diagnosed
- coronavirus disease
- ejection fraction
- chronic kidney disease
- prognostic factors
- respiratory syndrome coronavirus
- peritoneal dialysis
- type diabetes
- signaling pathway
- clinical practice
- patient reported
- metabolic syndrome
- human health
- adipose tissue
- smoking cessation
- replacement therapy